30% of patients with ALK-positive advanced non-small cell lung cancer have brain metastases at the first diagnosis. At present, there are innovative new lung cancer drugs that can break through the blood-brain barrier and effectively control and prevent brain metastases. The reporter learned that brigatinib, an innovative drug in the field of lung cancer, was officially approved by the National Medical Products Administration (NMPA) as a single drug for anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). ) treatment of patients. Professor Wu Yilong, chief expert of Guangdong Provincial People’s Hospital, said that brigatinib has obvious therapeutic effects on patients with brain metastases.
Lung cancer is one of the cancers with the highest morbidity and mortality worldwide. In China, the annual morbidity and mortality of lung cancer rank first among all malignant tumors. Among them, ALK-positive advanced non-small cell lung cancer is a relatively rare and dangerous subtype, and the number of new cases in my country is close to 35,000 every year. The average age of onset of these patients is relatively low, and they are generally associated with the predicament of a high incidence of brain metastases. Data show that 30% of patients with ALK-positive advanced non-small cell lung cancer have developed brain metastases at the time of initial diagnosis, and 75% of patients will develop brain progression within two years of treatment, seriously affecting survival and quality of life. At present, the drugs for the treatment of this disease are mainly targeted drugs, but drug resistance is prone to occur, and the drugs are subject to the blood-brain barrier and cannot have an effect on intracranial lesions. There are limitations in treatment, and there is an urgent need for innovative and effective therapeutic drugs to effectively control and prevent brain metastases, targeting the treatment of ALK fusion types and drug-resistant mutations, in order to improve the survival and quality of life of these patients.
The official approval of brigatinib brings a new treatment option for patients with ALK-positive advanced non-small cell lung cancer. This is a new ALK tyrosine kinase inhibitor. Its unique dimethyl phosphine oxide structure strengthens the binding force with ALK protein, enhances the drug activity, and also allows drugs to pass through the blood-brain barrier and maintain blood drugs in the brain. The concentration creates favorable conditions, and at the same time can widely inhibit various ALK fusion types and drug resistance mutations. The efficacy of the drug in prolonging patient survival, controlling brain metastases, and improving quality of life has been clinically verified. “.
Professor Wu Yilong, chief expert of Guangdong Provincial People’s Hospital
Professor Wu Yilong, chief expert of Guangdong Provincial People’s Hospital, said: The results of global clinical trials have shown a strong advantage in remission of intracranial lesions, and the treatment effect for patients with brain metastases is obvious. We are very much looking forward to the launch of brigatinib, which will allow patients to delay disease progression and greatly improve the patient’s health. The quality of life will also bring more treatment options and confidence to clinicians, and it is hoped that such innovative drugs can enter the national medical insurance as soon as possible, so that more patients can benefit from it.”
At present, Brigatinib has been approved in more than 40 countries and regions around the world, and has obtained FDA breakthrough therapy drug certification and orphan drug certification.
Written by: Southern Metropolis reporter Zeng Wenqiong
Intern: Xiao Tongdan